Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

CONCLUSIONS: Pembrolizumab and epacadostat demonstrated an ORR of 21% in this small cohort of recurrent OCCC. The rapid rate of accrual highlights the enthusiasm and need for therapeutic studies in patients with OCCC.PMID:38603953 | DOI:10.1016/j.ygyno.2024.03.027

Source: Gynecologic Oncology - April 11, 2024 Category: Cancer & Oncology Authors: Lilian T Gien Danielle M Enserro Matthew S Block Steven Waggoner Linda R Duska Andrea E Wahner-Hendrickson Premal H Thaker Floor Backes Michael Kidd Carolyn Y Muller Paul A DiSilvestro Allan Covens David M Gershenson Kathleen N Moore Carol Aghajanian Robe Source Type: research